GSK receives US approval for once-weekly type 2 diabetes treatment, TanzeumTM (albiglutide)

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved TanzeumTM (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes.

Source: GSK news - April 15, 2014 Category: Pharmaceuticals Source Type: news